StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Research analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Saturday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD opened at $1.64 on Friday. The company’s fifty day moving average is $1.74 and its two-hundred day moving average is $1.92. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

Several large investors have recently added to or reduced their stakes in TXMD. Prosperity Consulting Group LLC acquired a new position in TherapeuticsMD during the first quarter worth about $56,000. ADAR1 Capital Management LLC purchased a new position in shares of TherapeuticsMD during the fourth quarter valued at $612,000. Finally, Clearline Capital LP grew its holdings in shares of TherapeuticsMD by 18.9% during the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after buying an additional 101,282 shares in the last quarter. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.